APA

Minetto P., Guolo F., Clavio M., Kunkl A., Colombo N., Carminati E., Fugazza G., Matarese S., Guardo D., Ballerini F., Di Grazia C., Raiola A. M., Cagnetta A., Cea M., Miglino M., Lemoli R. M. & Gobbi M. (20191029). Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. : British journal of haematology.

Chicago

Minetto Paola, Guolo Fabio, Clavio Marino, Kunkl Annalisa, Colombo Nicoletta, Carminati Enrico, Fugazza Giuseppina, Matarese Simona, Guardo Daniela, Ballerini Filippo, Di Grazia Carmen, Raiola Anna M, Cagnetta Antonia, Cea Michele, Miglino Maurizio, Lemoli Roberto M and Gobbi Marco. 20191029. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. : British journal of haematology.

Harvard

Minetto P., Guolo F., Clavio M., Kunkl A., Colombo N., Carminati E., Fugazza G., Matarese S., Guardo D., Ballerini F., Di Grazia C., Raiola A. M., Cagnetta A., Cea M., Miglino M., Lemoli R. M. and Gobbi M. (20191029). Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. : British journal of haematology.

MLA

Minetto Paola, Guolo Fabio, Clavio Marino, Kunkl Annalisa, Colombo Nicoletta, Carminati Enrico, Fugazza Giuseppina, Matarese Simona, Guardo Daniela, Ballerini Filippo, Di Grazia Carmen, Raiola Anna M, Cagnetta Antonia, Cea Michele, Miglino Maurizio, Lemoli Roberto M and Gobbi Marco. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. : British journal of haematology. 20191029.